J&J Hid Risperdal Risks of Boy Breast Development, Jury Told
This article is for subscribers only.
Johnson & Johnson, which paid more than $2 billion to resolve a criminal probe over its antipsychotic drug Risperdal, knew the medicine caused boys to develop female breasts and failed to alert regulators, doctors and patients, a lawyer argued.
J&J kept quiet about research showing Risperdal caused abnormal breast development in boys to protect billions of dollars in sales of the drug, an attorney for the parents of an autistic man who developed size 46 DD breasts while on the medicine told a jury Friday. J&J misled the U.S. Food and Drug Administration about the antipsychotic’s safety, he added.